MARKET

TTPH

Tetraphase
TTPH
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-0.0963
1.320
0.5817
15,979,119.20
Merger Arbitrage Mondays - A Large Acquisition Ends The Energy Sector Deal Drought
Seeking Alpha · 07/27/2020 10:47
Merger Arbitrage Mondays - Dime Community Bancshares And Bridge Bancorp Combine In Merger Of Equals
Seeking Alpha - Article · 07/06/2020 14:11
Merger Arbitrage Mondays - Tetraphase Pharmaceuticals Finds A New Home
Seeking Alpha - Article · 06/29/2020 11:16
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
Benzinga · 06/25/2020 13:26
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.
GlobeNewswire · 06/24/2020 12:30
La Jolla to acquire Tetraphase Pharma
Seeking Alpha - Article · 06/24/2020 11:53
Tetraphase Terminated Deal With Melinta
Benzinga · 06/24/2020 11:38
UPDATE: Total Value Of La Jolla Purchase Of Tetraphase $43M In Upfront Cash Plus Potential Future Cash Payments Of Up To $16M
Benzinga · 06/24/2020 11:33
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TTPH. Analyze the recent business situations of Tetraphase through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TTPH stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.
EPS
Institutional Holdings
Institutions: 45
Institutional Holdings: 5.26M
% Owned: 72.41%
Shares Outstanding: 7.26M
TypeInstitutionsShares
Increased
8
1.31M
New
15
1.07M
Decreased
2
5.27K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.80%
Pharmaceuticals & Medical Research
+0.72%
Key Executives
Chairman/Independent Director
Leonard Patrick Gage
President/Chief Executive Officer/Director
Larry Edwards
Senior Vice President - Finance
Christopher Watt
Senior Vice President/General Counsel
Maria Stahl
Chief Scientific Officer
Jacques Dumas
Vice President
Larry Tsai
Director
Steven Boyd
Director
Guy Macdonald
Director
Keith Maher
Independent Director
Garen Bohlin
Independent Director
Jeffrey Chodakewitz
Independent Director
John Freund
Independent Director
Geraldine Henwood
Independent Director
Nancy Wysenski
No Data

Webull offers kinds of Tetraphase stock information, including NASDAQ:TTPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TTPH stock methods without spending real money on the virtual paper trading platform.